Video

Commenting on the findings from the SOLO1 trial of maintenance olaparib in newly diagnosed patients with BRCA-mutated ovarian cancer and the CORAIL trial of lurbinectedin in platinum-resistant relapsed setting, both presented at ESMO 2018 Congress, Dr Ana Oaknin says that BRCA mutation in ovarian cancer is a very important prognostic factor that we cannot miss anymore. According to Dr Oaknin, the ovarian cancer trials shouldn’t be based just on platinum-free interval or number of previous lines of therapy, but on molecular characteristics as well. Platinum resistance terminology should be refined based on the concept that the patient is suitable or not to receive further platinum therapy.As we are moving in the field of personalised medicine, we need to move forward another kind of trial's design in order to improve patients outcome.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen Novartis Nutricia Roche